The Centers for Medicare and Medicaid Services (CMS) announced Friday it will not be finalizing a rule proposed by the Biden administration that would have allowed Medicare and Medicaid ...

The previous administration attempted to have Medicare Part D and Medicaid cover anti-obesity drugs under the Contract Year 2026 MA and Part D rule, which would have substantially increased access ...

High-demand obesity treatments will not be covered under the federal government’s Medicare program, it was announced Friday. The Centers for Medicare and Medicaid Services said late Friday that ...

South Carolina Medicaid approved GLP-1s to treat obesity, placing it among the few state programs covering the drugs. But access remains limited.

House of Delegates today passed the Endocrine Society's resolution to improve access to anti-obesity medications.

My years dedicated to patient care have provided a deep understanding of the profound impact obesity has on individuals' lives, extending far beyond the numbers on a scale.

The Endocrine Society today endorsed the introduction of the bipartisan Treat and Reduce Obesity Act (TROA) in the Senate.

As a physician assistant in Charlotte, I have witnessed firsthand the transformative impact of new obesity medications on ...

My years dedicated to patient care have provided a deep understanding of the profound impact obesity has on individuals' ...

Despite axing a Biden-era proposal for government coverage of obesity drugs, health officials have signaled a potential path ...